A team from Estonia's University of Tartu and molecular diagnostics startup Selfdiagnostics has published a peer-reviewed study describing and clinically validating a recently developed point-of-care molecular assay to diagnose chlamydia infections.
Scientists from Seattle's PATH institute, the Fred Hutchinson Cancer Research Center, and Alere subsidiary TwistDx have published a paper demonstrating the rapid detection of HIV-1 proviral DNA using assays based on TwistDx's recombinase polymerase amplification, an isothermal am
Health management services and diagnostics firm Alere recently updated investors on the progress of a pair of nucleic acid testing platforms that are currently under development at the company and represent the firm's entrée into molecular diagnostics.
Health management-services and diagnostics firm Alere is developing a pair of nucleic acid testing platforms, representing the company's first major move into the molecular diagnostics space, according to recent company presentations.
This article has been corrected from a previous version that stated that Axxin disclosed in January that it is developing the NAT analyzer and iNAT platforms. In fact, Alere disclosed that it is developing these platforms.